Analysis: Bayer immune to pharma’s breakup bug?

By Ludwig Burger and Frank Siebelt FRANKFURT (Reuters) – Investors banking on Bayer to embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve. The diversified German healthcare group has an unusually high threshold for selling its odd-one-out MaterialScience unit, which is the world's largest maker of chemicals for insulation foams and transparent plastics for DVDs and car lights. …